{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:14:16Z","timestamp":1789010056934,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2009,12,4]],"date-time":"2009-12-04T00:00:00Z","timestamp":1259884800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s11102-009-0211-1","type":"journal-article","created":{"date-parts":[[2009,12,3]],"date-time":"2009-12-03T11:45:04Z","timestamp":1259840704000},"page":"418-424","source":"Crossref","is-referenced-by-count":59,"title":["Temozolomide (Temodar\u00ae) and capecitabine (Xeloda\u00ae) treatment of an aggressive corticotroph pituitary tumor"],"prefix":"10.1007","volume":"14","author":[{"given":"Marie S.","family":"Thearle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela U.","family":"Freda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey N.","family":"Bruce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Isaacson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoomi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Fine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,12,4]]},"reference":[{"key":"211_CR1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF02914988","volume":"6","author":"D Lubke","year":"1995","unstructured":"Lubke D, Saeger W, Ludecke DK (1995) Proliferation markers and EGF in ACTH-secreting adenomas and carcinomas of the pituitary. Endocr Pathol 6:45\u201355","journal-title":"Endocr Pathol"},{"key":"211_CR2","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1210\/jc.2004-2231","volume":"90","author":"GA Kaltsas","year":"2005","unstructured":"Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman AB (2005) Clinical review: diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab 90:3089\u20133099","journal-title":"J Clin Endocrinol Metab"},{"key":"211_CR3","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3171\/jns.2006.105.4.621","volume":"105","author":"CE Fadul","year":"2006","unstructured":"Fadul CE, Kominsky AL, Meyer LP, Kingman LS, Kinlaw WB, Rhodes CH, Eskey CJ, Simmons NE (2006) Long-term response of pituitary carcinoma to temozolomide. Report of two cases. J Neurosurg 105:621\u2013626","journal-title":"J Neurosurg"},{"key":"211_CR4","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.humpath.2006.07.014","volume":"38","author":"K Kovacs","year":"2007","unstructured":"Kovacs K, Horvath E, Syro LV, Uribe H, Penagos LC, Ortiz LD, Fadul CE (2007) Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: morphological findings. Hum Pathol 38:185\u2013189","journal-title":"Hum Pathol"},{"key":"211_CR5","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(06)70728-8","volume":"7","author":"S Lim","year":"2006","unstructured":"Lim S, Shahinian H, Maya MM, Yong W, Heaney AP (2006) Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol 7:518\u2013520","journal-title":"Lancet Oncol"},{"key":"211_CR6","doi-asserted-by":"crossref","unstructured":"Neff LM, Weil M, Cole A, Hedges TR, Shucart W, Lawrence D, Zhu JJ, Tischler AS, Lechan RM (2007) Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists. Pituitary","DOI":"10.1007\/s11102-007-0014-1"},{"key":"211_CR7","doi-asserted-by":"crossref","unstructured":"Hagen C, Schroeder H, Hansen S, Andersen M (2009) Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Eur J Endocrinol","DOI":"10.1530\/EJE-09-0389"},{"key":"211_CR8","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1365-2265.2008.03487.x","volume":"71","author":"AI McCormack","year":"2009","unstructured":"McCormack AI, McDonald KL, Gill AJ, Clark SJ, Burt MG, Campbell KA, Braund WJ, Little NS, Cook RJ, Grossman AB, Robinson BG, Clifton-Bligh RJ (2009) Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol (Oxf) 71:226\u2013233","journal-title":"Clin Endocrinol (Oxf)"},{"key":"211_CR9","doi-asserted-by":"crossref","first-page":"E773","DOI":"10.1227\/01.NEU.0000339115.12803.4E","volume":"64","author":"S Mohammed","year":"2009","unstructured":"Mohammed S, Kovacs K, Mason W, Smyth H, Cusimano MD (2009) Use of temozolomide in aggressive pituitary tumors: case report. Neurosurgery 64:E773\u2013E774 Discussion E774","journal-title":"Neurosurgery"},{"key":"211_CR10","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/(SICI)1097-0142(19970215)79:4<804::AID-CNCR18>3.0.CO;2-3","volume":"79","author":"PJ Pernicone","year":"1997","unstructured":"Pernicone PJ, Scheithauer BW, Sebo TJ, Kovacs KT, Horvath E, Young WF Jr, Lloyd RV, Davis DH, Guthrie BL, Schoene WC (1997) Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer 79:804\u2013812","journal-title":"Cancer"},{"key":"211_CR11","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000095526","volume":"83","author":"G Kontogeorgos","year":"2006","unstructured":"Kontogeorgos G (2006) Predictive markers of pituitary adenoma behavior. Neuroendocrinology 83:179\u2013188","journal-title":"Neuroendocrinology"},{"key":"211_CR12","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1210\/jc.2006-1328","volume":"92","author":"G Assie","year":"2007","unstructured":"Assie G, Bahurel H, Coste J, Silvera S, Kujas M, Dugue MA, Karray F, Dousset B, Bertherat J, Legmann P, Bertagna X (2007) Corticotroph tumor progression after adrenalectomy in Cushing\u2019s disease: A reappraisal of Nelson\u2019s syndrome. J Clin Endocrinol Metab 92:172\u2013179","journal-title":"J Clin Endocrinol Metab"},{"key":"211_CR13","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1210\/jc.80.1.165","volume":"80","author":"PJ Jenkins","year":"1995","unstructured":"Jenkins PJ, Trainer PJ, Plowman PN, Shand WS, Grossman AB, Wass JA, Besser GM (1995) The long-term outcome after adrenalectomy and prophylactic pituitary radiotherapy in adrenocorticotropin-dependent Cushing\u2019s syndrome. J Clin Endocrinol Metab 80:165\u2013171","journal-title":"J Clin Endocrinol Metab"},{"key":"211_CR14","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11102-005-1404-x","volume":"7","author":"J Hoek van der","year":"2004","unstructured":"van der Hoek J, Lamberts SW, Hofland LJ (2004) The role of somatostatin analogs in Cushing\u2019s disease. Pituitary 7:257\u2013264","journal-title":"Pituitary"},{"key":"211_CR15","first-page":"617","volume":"98","author":"E Horvath","year":"1980","unstructured":"Horvath E, Kovacs K, Killinger DW, Smyth HS, Platts ME, Singer W (1980) Silent corticotropic adenomas of the human pituitary gland: a histologic, immunocytologic, and ultrastructural study. Am J Pathol 98:617\u2013638","journal-title":"Am J Pathol"},{"key":"211_CR16","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1385\/EP:17:2:191","volume":"17","author":"LR Salgado","year":"2006","unstructured":"Salgado LR, Machado MC, Cukiert A, Liberman B, Kanamura CT, Alves VA (2006) Cushing\u2019s disease arising from a clinically nonfunctioning pituitary adenoma. Endocr Pathol 17:191\u2013199","journal-title":"Endocr Pathol"},{"key":"211_CR17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1023\/A:1009961925780","volume":"3","author":"EU Tan","year":"2000","unstructured":"Tan EU, Ho MS, Rajasoorya CR (2000) Metamorphosis of a non-functioning pituitary adenoma to Cushing\u2019s disease. Pituitary 3:117\u2013122","journal-title":"Pituitary"},{"key":"211_CR18","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1210\/jc.81.12.4272","volume":"81","author":"ML Raffin-Sanson","year":"1996","unstructured":"Raffin-Sanson ML, Massias JF, Dumont C, Raux-Demay MC, Proeschel MF, Luton JP, Bertagna X (1996) High plasma proopiomelanocortin in aggressive adrenocorticotropin-secreting tumors. J Clin Endocrinol Metab 81:4272\u20134277","journal-title":"J Clin Endocrinol Metab"},{"key":"211_CR19","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1530\/eje.0.1510173","volume":"151","author":"B Ambrosi","year":"2004","unstructured":"Ambrosi B, Dall\u2019Asta C, Cannavo S, Libe R, Vigo T, Epaminonda P, Chiodini I, Ferrero S, Trimarchi F, Arosio M, Beck-Peccoz P (2004) Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing\u2019s disease. Eur J Endocrinol 151:173\u2013178","journal-title":"Eur J Endocrinol"},{"key":"211_CR20","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1530\/eje.1.01994","volume":"153","author":"M Andreassen","year":"2005","unstructured":"Andreassen M, Kristensen LO (2005) Rosiglitazone for prevention or adjuvant treatment of Nelson\u2019s syndrome after bilateral adrenalectomy. Eur J Endocrinol 153:503\u2013505","journal-title":"Eur J Endocrinol"},{"key":"211_CR21","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1172\/JCI200316575","volume":"111","author":"AP Heaney","year":"2003","unstructured":"Heaney AP, Fernando M, Melmed S (2003) PPAR-gamma receptor ligands: novel therapy for pituitary adenomas. J Clin Invest 111:1381\u20131388","journal-title":"J Clin Invest"},{"key":"211_CR22","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1365-2265.2006.02501.x","volume":"64","author":"KR Mullan","year":"2006","unstructured":"Mullan KR, Leslie H, McCance DR, Sheridan B, Atkinson AB (2006) The PPAR-gamma activator rosiglitazone fails to lower plasma ACTH levels in patients with Nelson\u2019s syndrome. Clin Endocrinol (Oxf) 64:519\u2013522","journal-title":"Clin Endocrinol (Oxf)"},{"key":"211_CR23","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1097\/01.fpc.0000230410.07899.bc","volume":"16","author":"F Amatori","year":"2006","unstructured":"Amatori F, Di Paolo A, Del Tacca M, Fontanini G, Vannozzi F, Boldrini L, Bocci G, Lastella M, Danesi R (2006) Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients. Pharmacogenet Genomics 16:809\u2013816","journal-title":"Pharmacogenet Genomics"},{"key":"211_CR24","doi-asserted-by":"crossref","unstructured":"Isacoff WH Moss RA, Pecora AL, Fine RL 2006 Temozolomide\/capecitabine therapy for metastatic neuroendocrine tumors of the pancreas. A retrospective review. J Clin Oncol, ASCO Annual meeting proceedings part I 24:14023","DOI":"10.1200\/jco.2006.24.18_suppl.14023"},{"key":"211_CR25","first-page":"4216","volume":"23","author":"FineRL FD","year":"2005","unstructured":"FD FineRL, Schreibman SM (2005) Effective treatment of neuroendocrine tumors with temozolomide and capecitabine. J Clin Oncol, ASCO Annual meeting proceedings 23:4216","journal-title":"J Clin Oncol, ASCO Annual meeting proceedings"},{"key":"211_CR26","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/cncr.24053","volume":"115","author":"G Widhalm","year":"2009","unstructured":"Widhalm G, Wolfsberger S, Preusser M, Woehrer A, Kotter MR, Czech T, Marosi C, Knosp E (2009) O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment? Cancer 115:1070\u20131080","journal-title":"Cancer"},{"key":"211_CR27","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00401-007-0279-5","volume":"115","author":"K Kovacs","year":"2008","unstructured":"Kovacs K, Scheithauer BW, Lombardero M, McLendon RE, Syro LV, Uribe H, Ortiz LD, Penagos LC (2008) MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol 115:261\u2013262","journal-title":"Acta Neuropathol"},{"key":"211_CR28","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1158\/1078-0432.CCR-08-1476","volume":"15","author":"MH Kulke","year":"2009","unstructured":"Kulke MH, Hornick JL, Frauenhoffer C, Hooshmand S, Ryan DP, Enzinger PC, Meyerhardt JA, Clark JW, Stuart K, Fuchs CS, Redston MS (2009) O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 15:338\u2013345","journal-title":"Clin Cancer Res"},{"key":"211_CR29","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1002\/cncr.22127","volume":"107","author":"E Rivera","year":"2006","unstructured":"Rivera E, Meyers C, Groves M, Valero V, Francis D, Arun B, Broglio K, Yin G, Hortobagyi GN, Buchholz T (2006) Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer 107:1348\u20131354","journal-title":"Cancer"},{"key":"211_CR30","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1200\/JCO.2005.03.6046","volume":"24","author":"MH Kulke","year":"2006","unstructured":"Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS (2006) Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24:401\u2013406","journal-title":"J Clin Oncol"},{"key":"211_CR31","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1530\/EJE-08-0557","volume":"160","author":"VJ Moyes","year":"2009","unstructured":"Moyes VJ, Alusi G, Sabin HI, Evanson J, Berney DM, Kovacs K, Monson JP, Plowman PN, Drake WM (2009) Treatment of Nelson\u2019s syndrome with temozolomide. Eur J Endocrinol 160:115\u2013119","journal-title":"Eur J Endocrinol"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-009-0211-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11102-009-0211-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-009-0211-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,24]],"date-time":"2020-05-24T01:47:08Z","timestamp":1590284828000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11102-009-0211-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,4]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["211"],"URL":"https:\/\/doi.org\/10.1007\/s11102-009-0211-1","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,4]]}}}